natgillin/translations-raw huggingface dataset:
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on the surface of cells in the body.
Monoklonaalne antikeha on antikeha (teatud tüüpi valk), mis tunneb ära keharakkude pinnal esineva spetsiifilise struktuuri (nimetatakse antigeeniks) ja seondub sellega.
The most common side effects with Raptiva (seen in more than 1 patient in 10) are mild to moderate flu-like symptoms including headache, fever, chills, nausea (feeling sick), myalgia (muscle pain), and leucocytosis and lymphocytosis (increased white blood cell counts).
Kõige sagedamad Raptiva kõrvaltoimed (kirjeldatud rohkem kui ühel patsiendil kümnest) on kerge kuni mõõduka raskusega gripisarnased sümptomid, sealhulgas peavalu, palavik, külmavärinad, iiveldus, lihasvalu, ning leukotsütoos ja lümfotsütoos (vere valgeliblede arvu suurenemine).
It is given as a 12-week course, with a first dose of 0.7 mg per kilogram body weight followed by weekly injections of 1.0 mg/kg.
Esmaannusena manustatakse ravimit 0,7 mg kehamassi kilogrammi kohta, edaspidi 1,0 mg kehamassi kilogrammi kohta üks kord nädalas.
It should also not be used in patients who have had cancer, who have active tuberculosis or another severe infection, who have other types of psoriasis, or who have low levels of
Ravimit ei tohi kasutada ka patsientidel, kellel on olnud pahaloomuline kasvaja, kellel on aktiivne tuberkuloos või muu raske nakkus, kellel on muud tüüpi psoriaas või kelle
In the fifth study, overall, 166 (31%) of the 529 patients receiving Raptiva responded to treatment, compared with 11 (4%) of the 264 receiving placebo.
Viiendas uuringus saadi Raptivaga ravitulemus 166 patsiendil 529-st (31%), samas kui platseeboga saadi ravitulemus 11 patsiendil 264-st(4%).
Looking at the results of the first four studies taken together, 320 (26%) of the 1,213 patients receiving 1.0 mg/kg Raptiva per week responded to treatment, compared with 25 (4%) of the 715 receiving placebo.
Esimese nelja uuringu koondtulemuste alusel saadi Raptiva 1,0 mg/kg annuse manustamisel üks kord nädalas ravitulemus 320 patsiendil 1213-st (26%), samas kui platseeboga saadi ravitulemus 25 patsiendil 715-st (4%).
Raptiva is used for the treatment of adults with moderate to severe chronic (long-term) plaque psoriasis (a disease causing red, scaly patches on the skin).
Raptivat kasutatakse mõõduka kuni raske kroonilise (pikaajalise kuluga) naastulise psoriaasi (soomussammaspool; haigus, mis põhjustab nahale punaseid ketendavaid laike) raviks täiskasvanutel.
Efalizumab has been designed to bind to part of a protein called LFA-1 on the surface of lymphocytes, a type of white blood cell that is involved in the inflammation process.
Efalisumab seondub LFA-1 valgu osaga lümfotsüütide pinnal, mis on põletikuprotsessis osalevad teatud tüüpi vere valgelibled (leukotsüüdid).
For the full list of all side effects reported with Raptiva, see the Package Leaflet.
Raptiva kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
Looking only at the ‘high need' patients in this study, 30% of those receiving Raptiva responded to treatment, compared with 3% of those receiving
Nn uut ravimit väga vajavas patsientide rühmas saadi Raptivaga ravitulemus 30% patsientidest, samas kui platseeboga saadi ravitulemus 3% patsientidest.
PUVA is a type of treatment where the patient receives a medicine containing a compound called a ‘psoralen' before being exposed to ultraviolet
PUVA on raviviis, mille korral patsiendile antakse enne ultraviolettkiirgusega töötlemist psoraleeni sisaldavat ravimit.
Raptiva is a powder and solvent that are made up into a solution for injection.
Raptiva on pulber ja lahusti, millest segatakse kokku süstelahus.
The full EPAR for Raptiva can be found here.
Euroopa avaliku hindamisaruande täisteksti Raptiva kohta leiate aadressil siit.
Therefore, the Committee decided that Raptiva's benefits are greater than its risks for the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contra-indication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA.
Seetõttu otsustas inimtervishoius kasutatavate ravimite komitee, et Raptiva kasulikkus mõõduka kuni raske kroonilise naastulise psoriaasiga täiskasvanud patsientidel, kellel ei ole teiste süsteemsete ravimeetodite, sealhulgas tsüklosporiini, metotreksaadi või PUVA raviga saadud ravitulemust või kellel esinevad vastunäidustused neile ravimeetoditele või kes neid ravimeetodeid ei talu, ületab ravimi kasutamisega seotud riskid.
Raptiva was more effective than placebo at improving the symptoms of psoriasis.
Raptiva vähendas psoriaasi sümptomeid tõhusamalt kui platseebo.
What benefit has Raptiva shown during the studies?
Milles seisnes uuringute põhjal Raptiva kasulikkus?
It is used in patients who have failed to respond to or cannot take other systemic (whole-body) treatments for psoriasis, including ciclosporin, methotrexate and PUVA (psoralen ultraviolet-A).
Seda kasutatakse patsientidel, kellel ei ole teiste süsteemsete (kogu kehale mõjuvate) ravimimeetodite, sealhulgas tsüklosporiini, metotreksaadi ja PUVA-raviga (psoraleen ja ultraviolettkiirgus A) saadud ravitulemust või kes ei saa neid ravimeetodeid kasutada.
Raptiva treatment should be initiated by a doctor who specialises in dermatology (the treatment of skin conditions).
Ravi Raptivaga peab alustama dermatoloog (nahahaiguste arst).
It contains the active
See sisaldab toimeainet efalisumabi
Therapy should only be continued in patients who have responded to treatment.
Ravi võib jätkata vaid siis, kui ravi on andnud tulemusi.
The studies included patients who had not taken other treatments for psoriasis in the past, as well as those who had taken other treatments.
Tulemused olid sarnased nii neil, kes olid psoriaasi tõttu varem kasutanud süsteemseid ravimeetodeid, kui ka neil, kes sellist ravi varem saanud ei olnud.
Raptiva should be used with caution in patients who have problems with their liver or
Maksa- või neeruprobleemidega patsientidel tuleb Raptiva kasutamisel olla ettevaatlik.
Raptiva is given by injection under the skin.
Raptivat manustatakse nahaaluse (subkutaanse) süstena.
The European Commission granted a marketing authorisation valid throughout the European Union for Exforge HCT on 16 October 2009.
Euroopa Komisjon andis Exforge HCT müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. oktoobril 2009.
Exforge HCT is taken by mouth as one tablet once a day, at the same time of the day and preferably in the morning.
Exforge HCT-d võetakse suu kaudu üks tablett üks kord ööpäevas alati samal ajal, soovitavalt hommikul.
The full EPAR for Exforge HCT can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Euroopa avaliku hindamisaruande täistekst Exforge HCT kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The main measure of effectiveness was the average change in the blood pressure.
Efektiivsuse põhinäitaja oli vererõhu keskmine muutus.
It is available as tablets containing amlodipine, valsartan and hydrochlorothiazide in the following amounts: 5/160/12.5 mg, 10/160/12.5 mg, 5/160/25 mg, 10/160/25 mg and 10/320/25 mg.
Seda turustatakse tablettidena, mis sisaldavad amlodipiini, valsartaani ja hüdroklorotiasiidi järgmistes kogustes: 5/160/12,5 mg, 10/160/12,5 mg, 5/160/25 mg, 10/160/25 mg ja 10/320/25 mg.
Because the combination of the three active substances has been in use for a number of years, the company presented studies showing that the tablet containing all three substances is absorbed in the body in the same way as the separate tablets.
Et kolme toimeaine kombinatsiooni on kasutatud aastaid, esitas ettevõte uuringute tulemused, mis näitasid, et kolme toimeainet koos sisaldav tablett imendub organismis samal viisil kui toimeained eraldi tablettidena.
The CHMP therefore decided that Exforge HCT's benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Exforge HCT kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
For more information about treatment with Exforge HCT, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Exforge HCT-ga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exforge HCT.
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
This is a summary of the European public assessment report (EPAR) for Exforge HCT.
See on ravimi Exforge HCT Euroopa avaliku hindamisaruande kokkuvõte.
Valsartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a body hormone called angiotensin II.
Valsartaan on angiotensiin II retseptori antagonist, mis blokeerib organismi hormooni angiotensiin II toime.
amlodipine / valsartan / hydrochlorothiazide
amlodipiin/valsartaan/hüdroklorotiasiid
The CHMP noted that patients already taking the three active substances would be more likely to comply with their treatment if prescribed Exforge HCT which combines the three substances in a single tablet.
Inimravimite komitee märkis, et patsiendid, kes juba manustavad neid kolme toimeainet, järgivad raviskeemi tõenäoliselt paremini, kui neile anda Exforge HCT-d, milles on kolm toimeainet ühes tabletis.
The combination of the three active substances has an additive effect, reducing the blood pressure more than the individual medicines alone.
Nende kolme toimeaine kombinatsioonil on aditiivne toime: kombinatsioon alandab vererõhku rohkem kui toimeained eraldi.
Exforge HCT is a medicine that contains three active substances, amlodipine, valsartan and hydrochlorothiazide.
Exforge HCT on ravim, mis sisaldab kolme toimeainet: amlodipiini, valsartaani ja hüdroklorotiasiidi.
The daily dose of Exforge HCT should not exceed 10 mg of amlodipine, 320 mg of valsartan and 25 mg of hydrochlorothiazide.
Exforge HCT ööpäevane annus ei tohi olla üle 10 mg amlodipiini, 320 mg valsartaani ja 25 mg hüdroklorotiasiidi.
The three active substances in Exforge HCT are anti-hypertensive medicines that are already in use in the European Union (EU).
Exforge HCT kolm toimeainet on Euroopa Liidus juba kasutatavad kõrgvererõhuravimid.
In addition, one main study was carried out in 2,271 patients with moderate to severe hypertension with the highest strength of Exforge HCT (320 mg valsartan, 10 mg amlodipine and 25 mg hydrochlorothiazide).
Lisaks viidi läbi põhiuuring, milles osales 2271 mõõduka kuni raske kõrgvererõhutõvega patsienti, kellele anti Exforge HCT-d suurimas annuses (320 mg valsartaani, 10 mg amlodipiini ja 25 mg hüdroklorotiasiidi).
The most common side effects with Exforge HCT (seen in between 1 and 10 patients in 100) are hypokalaemia (low blood potassium levels), dizziness, headache, hypotension (low blood pressure), dyspepsia (heartburn), pollakiuria (abnormally frequent urination), fatigue (tiredness) and oedema (fluid retention).
Exforge HCT kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on hüpokaleemia (vere kaaliumivaegus), peapööritus, peavalu, hüpotensioon (madal vererõhk), düspepsia (kõrvetised), pollakiuuria (ebanormaalselt sage urineerimine), väsimus ja ödeem (turse).
Exforge HCT is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is already adequately controlled with a combination of amlodipine, valsartan and hydrochlorothiazide.
Exforge HCT-d kasutatakse essentsiaalse hüpertensiooniga (kõrgvererõhutõvega) täiskasvanutel, kelle vererõhk allub piisavalt ravile amlodipiini, valsartaani ja hüdroklorotiasiidi kombinatsiooniga.
By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone having an effect, allowing the blood vessels to widen and blood pressure to reduce.
Blokeerides retseptorid, millega angiotensiin II tavaliselt seondub, peatab valsartaan hormooni toime ja soodustab veresoonte laienemist, nii et vererõhk väheneb.
The main study showed the benefit of the highest strength of Exforge HCT in lowering the blood pressure.
Põhiuuring näitas Exforge HCT suurima annuse mõju vererõhu alandamisel.
By reducing the flow of calcium into the cells, amlodipine prevents the cells from contracting and helps the blood vessel walls to relax and widen, thereby reducing blood pressure.
Vähendades kaltsiumi sissevoolu rakkudesse, ennetab amlodipiin rakkude kokkutõmbumist ja soodustab veresoonte lõdvestumist ning laienemist, mis alandab vererõhku.
The dose of Exforge HCT to be used is the same as the doses of three individual active substances that the patient was taking before.
Exforge HCT-d tuleb anda samas annuses kui kolme toimeainet, mida patsient varem eraldi võttis.
Treatment with the highest strength of Exforge HCT was more effective at treating hypertension than dual combinations containing any of the two active substances.
Ravi Exforge HCT suurima annusega oli vererõhu alandamisel efektiivsem kui ravi mis tahes kahe toimeaine kombinatsiooniga.
Exforge HCT must not be used in people who are hypersensitive (allergic) to the active substances, to other sulfonamides, to dihydropyridine derivatives or to any of the other ingredients in Exforge HCT.
Exforge HCT-d ei tohi kasutada patsiendid, kes on selle toimeainete, teiste sulfoonamiidide, dihüdropüridiini derivaatide klassi kuuluvate toimeainete või Exforge HCT mis tahes muude koostisainete suhtes ülitundlikud (allergilised).
The average reduction in blood pressure was around 39.7/24.7 mmHg in patients taking Exforge HCT compared with 32/19.7 mmHg, 33.5/21.5 mmHg and 31.5/19.5 mmHg in patients taking valsartan/hydrochlorothiazide, valsartan/amlodipine and hydrochlorothiazide/amlodipine combinations, respectively.
Exforge HCT-d manustanud patsientidel alanes vererõhk keskmiselt 39,7/24,7 mmHg võrra, ent valsartaani-hüdroklorotiasiidi, valsartaani-amlodipiini või hüdroklorotiasiidi-amlodipiini kombinatsiooni manustanud patsientidel vastavalt 32/19,7 mmHg, 33,5/21,5 mmHg ja 31,5/19,5 mmHg võrra.
By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.
Vererõhu langusega vähenevad kõrgvererõhuga seotud riskid, näiteks insuldirisk.
Other information about Exforge HCT
Muu teave Exforge HCT kohta
For the full list of all side effects reported with Exforge HCT, see the package leaflet.
Exforge HCT kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
It must also not be used in patients who have liver or bile problems (such as jaundice), severe kidney problems, anuria (a condition in which a patient cannot make or pass urine) or in patients undergoing dialysis (a blood clearance technique).
Ravimit ei tohi kasutada patsiendid, kellel on maksa- või sapipõiehaigus (nt ikterus), raske neeruhaigus, anuuria (kuseerituse puudumine) ega patsiendid, kellele tehakse dialüüsi (teatud verepuhastustehnika).
Patients received either Exforge HCT or one of the three combinations containing only two of the active substances for eight weeks.
Patsiendid manustasid kaheksa nädala jooksul kas Exforge HCT-d või kahe toimeaine kolmest kombinatsioonist ühte kombinatsiooni.
Finally, Exforge HCT must not be used in patients with hypokalaemia (low blood potassium levels), hyponatraemia (low blood sodium levels) and hypercalcaemia (high blood calcium levels) that do not respond to treatment and in patients with hyperuricaemia (high blood levels of uric acid) that causes symptoms.
Exforge HCT-d ei tohi anda ka patsientidele, kellel on ravile allumatu hüpokaleemia (vere kaaliumivaegus), hüponatreemia (vere naatriumivaegus) või hüperkaltseemia (suur kaltsiumisisaldus veres), samuti patsientidele, kellel on hüperurikeemia (suur kusihappe sisaldus veres), mis põhjustab haigusnähte.
What is Exforge HCT?
Mis on Exforge HCT?
Why has Exforge HCT been approved?
Miks Exforge HCT heaks kiideti?
What is the risk associated with Exforge HCT?
Mis riskid Exforge HCT-ga kaasnevad?
It works by increasing urine output, reducing the volume of fluid in the blood and lowering the blood pressure.
Hüdroklorotiasiid on diureetikum ehk aine, mis suurendab uriinieritust, vähendades vedeliku hulka veres ja alandades vererõhku.
What benefit has Exforge HCT shown during the studies?
Milles seisneb uuringute põhjal Exforge HCT kasulikkus?
For all doses, Exforge HCT also met requirements to prove that it was comparable to the combinations of the individual active substances taken seperately.
Exforge HCT kõigi annuste kohta tõendati, et nende mõju on sama mis kolmel toimeainel eraldi võetuna.
How has Exforge HCT been studied?
Kuidas Exforge HCT-d uuriti?
How is Exforge HCT used?
Kuidas Exforge HCT toimib?
Exforge HCT must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.
II tüüpi diabeediga või mõõduka või raske neerupuudulikkusega patsiendid ei tohi kasutada Exforge HCT-d koos aliskireeni sisaldavate ravimitega (samuti essentsiaalse hüpertensiooni ravimid).
Hydrochlorothiazide is a diuretic.
Exforge HCT on retseptiravim.
What is Exforge HCT used for?
Milleks Exforge HCT-d kasutatakse?
Cuprior should be taken on an empty stomach, at least one hour before or two hours after meals.
Cupriori tuleb võtta tühja kõhuga vähemalt üks tund enne või kaks tundi pärast sööki.
What measures are being taken to ensure the safe and effective use of Cuprior?
Mis meetmed võetakse, et tagada Cupriori ohutu ja efektiivne kasutamine?
Cuprior is available as 150 mg tablets.
Cupriori turustatakse 150 mg tablettidena.
In adults, the total recommended daily dose is from 3 to 6.5 tablets, and in children from 1.5 to 4 tablets.
Täiskasvanutel on soovitatav ööpäevane koguannus 36,5 tabletti ja lastel 1,5-4 tabletti.
Cuprior trientine
Cuprior trientiin
The full EPAR for Cuprior can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Euroopa avaliku hindamisaruande täistekst Cupriori kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The tablets are taken in 2 to 4 divided doses.
Tablette võetakse jagatuna 2-4 annuseks.
This means that it is similar to a ‘reference medicine' (in this case Trientine Dihydrochloride 300 mg capsules) also containing trientine.
See tähendab, et see sarnaneb võrdlusravimiga Trientine Dihydrochloride (300 mg kapslid), mis sisaldab samuti trientiini.
Other information about Cuprior
Muu teave Cupriori kohta
The difference between Cuprior and the reference medicine is that Cuprior contains another form of trientine (trientine tetrahydrochloride) and does not need to be stored in a refrigerator.
Cupriori ja selle võrdlusravimi erinevus on, et Cuprior sisaldab trientiini muus vormis (trientiintetravesinikkloriidina) ja seda ei pea säilitama külmikus.
The company provided data from the published literature, which show that trientine significantly increases copper elimination in the urine.
Ettevõte esitas avaldatud kirjandusest pärit andmed, mis tõendavad, et trientiin suurendab oluliselt vase eritumist uriiniga.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cuprior's benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Cupriori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
This is a summary of the European public assessment report (EPAR) for Cuprior.
See on ravimi Cuprior Euroopa avaliku hindamisaruande kokkuvõte.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cuprior have been included in the summary of product characteristics and the package leaflet.
Cupriori ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
Since Cuprior is a hybrid medicine, its benefits and risks are taken as being the same as the reference medicine's.
Et Cuprior on hübriidravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
Why is Cuprior approved?
Miks Cuprior heaks kiideti?
It is not intended to provide practical advice on how to use Cuprior.
Hindamisaruandes ei anta Cupriori kasutamise praktilisi nõuandeid.
The CHMP noted that trientine has been used for over 30 years to treat patients with Wilson's disease.
Inimravimite komitee märkis, et trientiini on Wilsoni tõvega patsientide raviks kasutatud üle 30 aasta.
What is Cuprior and what is it used for?
Mis on Cuprior ja milleks seda kasutatakse?
Cuprior can only be obtained with a prescription and treatment should be started by a specialist with experience in the management of Wilson's disease.
Cuprior on retseptiravim ja ravi peab alustama Wilsoni tõve ravis kogenud spetsialist.
Although Cuprior releases more trientine in the body than the reference medicine, this difference can be addressed by lowering the dose, which is in any case adjusted according to patient response and levels of copper in the body.
Kuigi Cuprior tekitab organismis suurema trientiinisisalduse kui võrdlusravim, on annused selle tõttu väiksemad ning igal juhul kohandatakse annuseid patsiendi ravivastuse ja organismi vasesisalduse järgi.
Cuprior is used in patients who cannot take D-penicillamine, another medicine for this condition.
Cupriori kasutatakse patsientidel, kes ei saa kasutada Dpenitsillamiini (samuti selle haiguse ravim).
It works by attaching to copper in the body and forming a complex that is then eliminated in the urine.
See seondub organismis vasega, moodustades keemilise kompleksi, mis seejärel eritub uriiniga.
Cuprior contains the active substance trientine.
Cuprior sisaldab toimeainena trientiini.
Doses are adjusted according to patient response and levels of copper in the body.
Annuseid kohandatakse patsiendi ravivastuse ja organismi vasesisalduse järgi.
The company also carried out a study to compare the levels of trientine in the blood after having taken Cuprior with those for the reference medicine.
Peale selle tegi ettevõte uuringu, et võrrelda vere trientiinisisaldust pärast Cupriori ja võrdlusravimi manustamist.
To take account of this difference, Cuprior is used at lower doses.
Selle erinevuse arvestamiseks kasutatakse Cupriori väiksemates annustes.
Results showed that Cuprior produces higher levels of the active substance in the blood than the reference medicine.
Uuringu järgi tekitab Cuprior veres suurema toimeainesisalduse kui võrdlusravim.
For practical information about using Cuprior, patients should read the package leaflet or contact their doctor or pharmacist.
Kui vajate Cupriori kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
For more information about treatment with Cuprior, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Cuprioriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
What are the benefits and risks of Cuprior?
Milles seisneb Cupriori kasulikkus ja mis riskid ravimiga kaasnevad?
It is a hybrid medicine.
Cuprior on hübriidravim.
How is Cuprior used?
Kuidas Cupriori kasutatakse?
Cuprior is a medicine used to treat patients aged 5 years and older with Wilson's disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage.
Wilsoni tõbi on geneetiline haigus, mille korral toidust imendunud vask ladestub organismis, eriti maksas ja peaajus, kahjustades organismi.